RxDoctor Payments Data

Deepti Govathoti, MD

Family Medicine · Carthage, TXNPI 1316190754

Payments from drug & device makers

$213in general payments, 2019–2025

Across 11 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48
  • Sunovion Pharmaceuticals Inc.$29
  • Mylan Specialty L.p.$26
  • Neurocrine Biosciences, Inc.$24
  • Pfizer$21
  • Acadia Pharmaceuticals Inc$20
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$213100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$213 in reported general payments places this provider in the 35th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$221,320
Medicare patients
629
Services billed
3,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban608$195,338
JardianceEmpagliflozin259$109,935
TradjentaLinagliptin348$108,173
OzempicSemaglutide52$71,983
EntrestoSacubitril/Valsartan105$51,868
IngrezzaValbenazine Tosylate13$50,239
FarxigaDapagliflozin Propanediol117$42,073
NuplazidPimavanserin Tartrate17$40,889
XareltoRivaroxaban138$40,852
NuedextaDextromethorphan Hbr/Quinidine53$40,323
TrulicityDulaglutide46$40,295
JanuviaSitagliptin Phosphate126$38,740
CreonLipase/Protease/Amylase28$36,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$34,827
MounjaroTirzepatide31$34,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$195,338608 claims
Neurocrine Biosciences, Inc.Ingrezza$24$50,23913 claims
Acadia Pharmaceuticals IncNuplazid$20$40,88917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Carthage

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →